Supportive and Palliative Care (GI) Flashcards
Why does CINV, CID and mucositis occur?
Chemo not only kills cancer cells but also fast reproducing cells –> damage to mucosa of oral cavity, pharynx, larynx, esophagus and GIT
Explain the emesis pathway in CINV
Central pathway via CNS: Vomiting center in medulla send signals to vagus nerve to release substance P that is taken up by NK 1 receptors causing CINV.
Peripheral pathway via gut: Enterochromaffin cells of the GIT releases serotonin that is taken up by the 5HT3 receptors in vagal afferent, causing CINV
Central pathway mainly causes which phase of CINV?
Delayed phase
Peripheral pathway mainly causes which phase of CINV?
Acute phase
Describe acute CINV
- Usually starts within 1-2hrs after administration
- Peak intensity within 5-6hrs, resolution at 12-24hrs
Describe delayed CINV
- Peak onset 48-72hrs after chemo, diminishing after 1-3days
- Occurs in 50-90% (highly emetogenic regimens), 35-80% (moderately emetogenic therapy) of pts
What is breakthrough CINV?
N/V occurring despite preventive therapy
What is anticipatory CINV?
- Conditioned response
- Assoc with uncontrolled emesis prior chemotherapy
What is refractory CINV?
- N/V occurring during subsequent cycles of chemotherapy when antiemetic prophylaxis or rescue therapy has failed in previous cycles
Examples of high emetic risk of IV drugs (>90% freq of emesis)
- AC combination defined as any chemotherapy regimen that contains an anthracycline (eg. doxorubicin) and cyclophosphamide.
- Carboplatin AUC >=4
- Cisplatin
One example of low emetic risk of IV drugs (10-30% freq)
Etoposide
Risk factors for CINV
- Younger age (<50 years old)
- Female gender
- History of low prior chronic alcohol intake (<1 glass of alcohol/day)
- History of previous chemotherapy induced emesis
- History of motion sickness
- History of emesis during past pregnancy
- Anxiety
What classes of antiemetics are given for high emetogenic risk?
Acute (given on day 1):
- NK1
- 5HT3
- DEXA
- +/- OLA
Delayed (day 2 onwards):
- DEXA D2-4
- +/- OLA D2-4
What classes of antiemetics are given for moderate emetogenic risk?
Acute:
- 5HT3
- DEX
Delayed:
- DEX D2-3
What classes of antiemetics are given for low emetogenic risk?
Acute only: 5HT3 or DEX or DOPA
MOA of Neurokinin-1 (NK1) antagonist
Binds to NK-1 receptors, which prevents substance P (nociceptive neurotransmitter) from binding. Attenuates vagal afferent signals and exert antiemetic effect
Examples of NK1 antagonist and their doses
- Aprepitant (Emend) 125 mg PO day 1, 80 mg PO days 2-3
- Netupitant 300mg (+ 5HT3 Palonosetron 0.5mg) (Akynzeo) PO day 1
What is the advantage of using Akynzeo over Emend?
Akynzeo is only 1 day course vs Emend which is a 3 day course
Adverse effects of NK1 antagonist
Low frequency of fatigue, weakness, nausea, hiccups
DDI with NK1 antagonist
- Steroids
- Warfarin
- Benzodiazepines (increase benzodiazepine concentrations due to reduced metabolism)
- Certain chemotherapy eg Ifosfamide (decreases metabolism of ifosfamide) → chemotoxicity
MOA of Serotonin (5HT3) antagonist
Block 5HT-3 receptors peripherally in the gastrointestinal tract and centrally in the medulla
Examples of 5HT3 antagonist
- IV/PO Ondansetron
- IV/PO Granisetron (longer acting that ondansetron, but cost $$$ more)
- IV/PO Palonosetron (PO form available in combination with NK-1 antagonist Netupitant given on Day 1 of chemotherapy)
Dosing of ondansetron and granisetron
- IV/PO Ondansetron 8-16mg OD Day 1, IV/PO Ondansetron 8mg BD Day 2 onwards (max 16mg/dose)
- IV/PO Granisetron 1mg OD Day 1, IV/PO Granisetron 1mg OM Day 2 onwards
Adverse effects of 5HT3 antagonist
Headache and constipation - occurring in 15% of patients.
May cause QTc prolongation (black box warning)